Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galeterone vs Enzalutamide in AR-V7+ mCRPC
NCT02438007Phase 3Terminated
- Sponsor
- LTN Pharmaceuticals, Inc.
- Start
- Jun 2015
- Primary completion
- Jul 2016
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
A Phase 3 trial of galeterone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by LTN Pharmaceuticals, Inc.. Started Jun 2015; status: terminated.
02
Drugs
galeterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02438007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02438007.